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ABSTRACT The mycobacterial cell wall affords natural resistance to antibiotics. Antimi-
crobial peptides (AMPs) modify the surface properties of mycobacteria and can act syn-
ergistically with antibiotics from differing classes. Here, we investigate the response of
Mycobacterium smegmatis to the presence of rifampin or capreomycin, either alone or in
combination with two synthetic, cationic, -helical AMPs that are distinguished by the
presence (D-LAK120-HP13) or absence (D-LAK120-A) of a kink-inducing proline. Using a
combination of high-resolution magic angle spinning nuclear magnetic resonance (HR-
MAS NMR) metabolomics, diphenylhexatriene (DPH) fluorescence anisotropy measure-
ments, and laurdan emission spectroscopy, we show that M. smegmatis responds to
challenge with rifampin or capreomycin by substantially altering its metabolism and, in
particular, by remodeling the cell envelope. Overall, the changes are consistent with a
reduction of trehalose dimycolate and an increase of trehalose monomycolate and are
associated with increased rigidity of the mycolic acid layer observed following challenge
by capreomycin but not rifampin. Challenge with D-LAK120-A or D-LAK120-HP13 in-
duced no or modest changes, respectively, in mycomembrane metabolites and did not
induce a significant increase in the rigidity of the mycolic acid layer. Furthermore, the re-
sponse to rifampin or capreomycin was significantly reduced when these were com-
bined with D-LAK120-HP13 and D-LAK120-A, respectively, suggesting a possible mecha-
nism for the synergy of these combinations. The remodeling of the mycomembrane in
M. smegmatis is therefore identified as an important countermeasure deployed against
rifampin or capreomycin, but this can be mitigated and the efficacy of rifampin or
capreomycin potentiated by combining the drug with AMPs.
IMPORTANCE We have used a combined NMR metabolomics/biophysical approach
to better understand differences in the mechanisms of two closely related antimicro-
bial peptides, as well as the response of the model organism Mycobacterium smeg-
matis to challenge with first- or second-line antibiotics used against mycobacterial
pathogens. We show that, in addition to membrane damage, the triggering of oxi-
dative stress may be an important part of the mechanism of action of one AMP. The
metabolic shift that accompanied rifampin and, particularly, capreomycin challenge
was associated with modest and more dramatic changes, respectively, in the my-
comembrane, providing a rationale for how the response to one antibiotic may af-
fect bacterial penetration and, hence, the action of another. This study presents the
first insights into how antimicrobial peptides may operate synergistically with exist-
ing antibiotics whose efficacy is waning or sensitize MDR mycobacteria and/or latent
mycobacterial infections to them, prolonging the useful life of these drugs.
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Mycobacterium spp. are responsible for a variety of diseases, including tuberculosis(TB), leprosy, pulmonary disease, lymphadenitis, and skin and disseminated dis-
eases. Although the incidence of tuberculosis is falling globally at a rate of about 2%
per year, it still carries the greatest worldwide disease burden, with 10.4 million people
falling ill with TB in 2016 and 1.7 million deaths (1). Infections due to nontuberculous
mycobacteria are also increasingly recognized (2). Although the reduced global inci-
dence of tuberculosis is welcome, first-line therapies for tuberculosis are increasingly
failing, with 600,000 new cases of tuberculosis resistant to the most effective first-line
antibiotic, rifampin. Of these, 490,000 cases were multidrug resistant (MDR), and a
substantial proportion of these were extensively drug-resistant (XDR). While 95% of
tuberculosis deaths occur in low- and middle-income countries (LMICs), tuberculosis is
also an increasing problem in the developed world, where reactivation of latent
tuberculosis infections is of particular concern (3). Mycobacteria are intrinsically resis-
tant to many antibiotics that are effective against other bacteria, and this is thought to
be due to the superior protection offered by both mycobacterial outer (7- to 8-nm
thick) and inner (6- to 7-nm) membranes, a layer of arabinogalactan-peptidoglycan (6
to 7 nm), and a periplasm (14 to 17 nm) containing lipomannan and lipoarabinoman-
nan, resulting in a cell envelope between 33 and 39 nm thick (4, 5). The emergence of
resistance to the limited number of existing therapies for tuberculosis has focused
attention on the particular problems associated with finding drugs capable of breach-
ing the mycobacterial cell wall, since this may offer a means of either directly killing
mycobacterial pathogens or of resensitizing them to existing first-line antibiotics.
In this regard, antimicrobial peptides (AMPs) are of considerable interest, since their
mechanisms of action are often associated with direct damage to bacterial plasma
membranes and/or penetration within the bacterial cytoplasm to access intracellular
targets (6), and these actions often result in rapid bacterial cell death—a property that
may be desirable in reducing the incidence of resistance to AMPs. Antimicrobial
peptides are therefore increasingly being evaluated as antituberculosis agents (7, 8).
Indeed, not only have antimicrobial peptides been evaluated in isolation, combina-
tions of antimicrobial peptides with first-line antimycobacterial agents have already
been shown to be effective (6, 9–11). All D-amino acid isomers of these peptides
displayed improved stability and enhanced mycobacterial selectivity (12).
Our own research has focused on a series of highly cationic antimicrobial peptides
comprised of D-amino acids, rationally designed to adopt -helix conformations within
biological membranes (13). These AMPs have a detergent-like ability to enable disrup-
tion of colonies of Mycobacterium tuberculosis strain H37Ra (13), are able to inhibit the
growth of MDR and XDR strains of M. tuberculosis when cultured in THP-1 macrophage
cells, and potentiate the activity of the first-line antibiotic isoniazid in vitro (14). The
D-LAK peptides were designed to be cationic and amphipathic, with the angle sub-
tended by the positively charged lysine residues when the peptide adopts an idealized
-helix conformation that is modified to enhance disruption of anionic model mem-
branes (13). Further, the role of conformational flexibility was investigated and proline
residues were introduced to disrupt the -helix. The positioning of this proline kink was
shown to be important and could enhance activity against Gram-negative bacteria
while also mitigating hemolysis (13). Conformational flexibility is a key property of
potent antimicrobial peptides, such as pleurocidin, which is associated with greater
penetration of bacterial membranes and the ability to reach intracellular targets (14,
15). A transcriptomic and NMR metabolomic approach to understanding the mecha-
nism of action of D-LAK120-HP13 supports an ability to penetrate within Gram-negative
bacteria (16). Interestingly, however, the proline-containing D-LAK peptides did not
always outperform their proline-free analogues when tested against Mycobacterium
tuberculosis H37Ra, highlighting that the mechanism of action against mycobacteria is
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likely to be distinct from that which is effective against Gram-negative bacteria.
Consequently, our understanding of the structural features that promote antimycobac-
terial activity is poorly developed.
To address this gap in our understanding, we have investigated in more detail how
Mycobacterium smegmatis responds to challenge with proline-free (D-LAK120-A) and
proline-containing (D-LAK120-HP13) D-LAK peptides. We examined the activity of and
bacterial response to the combination of each peptide with rifampin or capreomycin to
investigate the mechanism of the observed, albeit modest, synergy. Testing the hy-
pothesis that the membrane activity of the D-LAK peptides is key to both their
antimycobacterial activity and their ability to potentiate the activity of rifampin and
capreomycin, we incorporated high-resolution magic angle spinning nuclear magnetic
resonance (HR-MAS NMR) metabolomics with fluorescence spectroscopy of M. smeg-
matis membrane-incorporated trans-1,6-diphenyl-1,3,5-hexatriene (DPH) and laurdan
dyes, which are sensitive to changes in membrane fluidity and order, respectively.
These techniques were able to distinguish between the two D-LAK peptides and
revealed that, when challenged with subinhibitory concentrations of rifampin or
capreomycin, M. smegmatis remodeled its membrane. These observations suggest why
and how antimicrobial peptides may act and may be modified to improve their ability
to potentiate existing antimycobacterial treatments.
RESULTS
Action of D-LAK peptides onM. smegmatis. The action of the two D-LAK AMPs on
M. smegmatis was first investigated to confirm that, as suspected from their activity
against M. smegmatis, the peptides acted on the mycobacterial cell wall. Confocal
microscopic investigation of M. smegmatis strain mc2 155 challenged with sub- or
supra-MICs of D-LAK120-A, D-LAK120-HP13, or rifampin indicate that both peptides,
but not rifampin, cause the bacteria to stain positive with fluorescein isothiocyanate
(FITC)-labeled, 150-kDa dextran (Fig. 1). FITC-dextran has been used in a number of
studies with vesicles to probe the membrane permeabilization ability of diverse anti-
microbial peptides, and a series of labeled dextran conjugates are available to measure
FIG 1 AMPs render Mycobacterium smegmatis permeable to fluorescein isothiocyanate (FITC)-dextran. Confocal
microscope images of 1.1 108 CFU/mlM. smegmatismc2 155 either unchallenged (A) or challenged with rifampin
alone (D) or D-LAK120-A (B and E) or D-LAK120-HP13 (C and F) at 0.5 MIC (B and C) or 2 MIC (E and F). In contrast
to the results for rifampin, both peptides facilitate absorption or adsorption of the 150-kDa fluorescently labeled
dextran.
M. smegmatis HR-MAS NMR
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the size of pores that may be formed by antimicrobial peptides (17–20). In the case of
melittin, dextran of 4 kDa was readily able to escape from loaded vesicles, but much
less of the 50-kDa analogue was released. This indicated that a pore with a defined
diameter of 25 to 30 Å is formed (17). In contrast, other peptides facilitate the escape
of dextrans across the full range of sizes tested, but complete leakage is never achieved
(19, 20). These results have been interpreted as evidence for rather large but transient
lesions (19). At 150 kDa, the dextran used in the present study is substantially larger
than those used in previous studies of escape from lipid vesicles, and it is not possible
from images with this resolution to determine whether the labeled dextran has
penetrated within the bacterial cells. It is may be that the same functionality that causes
D-LAK peptides to prevent aggregation of M. tuberculosis colonies also enables the
dextran to adsorb to the surface of M. smegmatis.
Transmission electron microscopy (TEM) was exploited to visualize the effect of
D-LAK peptides on the ultrastructural changes of M. smegmatis (Fig. 2). Unchallenged
cells have characteristic lipid inclusions, a regular rod-shaped cell body with well-
defined intact cell membranes, and homogeneous cytoplasm (Fig. 2A). The cell enve-
lope was distinctly visible, with cytosol bound by the plasma membrane, surrounded by
an internal and then an outer electron-dense layer (21, 22). The cell content was slightly
pulled away in some control cells, which is attributed to the sample preparation
process. Membrane ruffling was observed after treating M. smegmatis mc2 155 at 1
MIC with D-LAK120-A (Fig. 2B) or D-LAK-120-HP13 (Fig. 2D) for 5 min. Cytoplasmic
retraction was observed as the inner cell membrane detached from the outer cell wall.
This phenomenon was reported when Escherichia coli and Bacillus subtilis were exposed
FIG 2 AMPs disrupt membrane surface of M. smegmatis. Transmission electron micrographs of 1.1  108 CFU/ml M. smegmatis mc2 155 either
unchallenged (A) or challenged with D-LAK120-A (B and C) or D-LAK120-HP13 (D and E) for 5 (B and D) or 30 (C and E) min. r, membrane ruffling;
cr, cytoplasmic retraction; m, mesosome.
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to antimicrobial peptides (23). Similar findings have been observed for exposure of
Mycobacterium tuberculosis (Erdman strain) to antimicrobial peptides; granulysin dem-
onstrated inner cell membrane detachment as observed in osmotic lysis (24). The
reduction in membrane uniformity suggests a cell-penetrating ability for the D-LAK
peptides. Peptide treatment also induced notable intracellular changes, with clumped
cytosol and an increased amount of mesosome formation. Mesosome structures have
been observed previously in bacteria challenged by antimicrobial peptides (25, 26). The
formation of mesosomes was suggested as a repair mechanism by bacteria to combat
cell lysis (27). Prolonged treatment (30 min) with D-LAK peptides resulted in large-scale
cell lysis and the presence of cell debris (Fig. 2C and E). This indicates that the fate of
bacteria challenged with inhibitory concentrations of D-LAK peptides is disturbed cell
membranes and cell wall disintegration, membrane rupture, and release of intracellular
contents.
Activity of D-LAK peptides against M. smegmatis alone or in combination with
rifampin or capreomycin. All four antibiotics were tested in isolation against M. smeg-
matismc2 155 both in the presence and absence of tyloxapol, a nonionic liquid polymer
which is often included when growing mycobacteria in planktonic suspension, to
prevent clumping (Table 1). As a detergent, it can be expected to disrupt membranes
and remove components of the cell envelope and may facilitate the entry of some
antimicrobial drugs. As such, we have studied the behavior of M. smegmatis mc2 155
with and without this common additive to the growth medium. Notably, both peptides
and rifampin were more potent when tyloxapol was present in the culture medium, but
the activity of capreomycin was unchanged.
Combinations of rifampin or capreomycin with each of the D-LAK peptides were
then tested (Table 2). In the absence of tyloxapol, the combinations of capreomycin and
the D-LAK peptides are modestly synergistic. Effective inhibition is achieved by
D-LAK120-A and capreomycin when used in combination, with approximately a third of
each agent required to achieve the same effect as when each agent is used alone. The
effect is more marked when the combination is used in the presence of tyloxapol, with
a fractional inhibitory concentration (FIC) of 0.5, which is widely accepted as a
TABLE 1 MICs of D-LAK peptides, rifampin, and capreomycin against M. smegmatis mc2
155 when used alone or in combination, in the presence or absence of tyloxapol
Antimicrobial measured (antimicrobial
used in combination)
Mean MIC50  SE (M) with:
Tyloxapol No tyloxapol
Rifampin 19.9  3.04 38.1  5.83
Capreomycin 1.72  0.43 1.35  0.25
D-LAK120-A 0.82  0.07 1.68  0.43
D-LAK120-HP13 0.63  0.03 1.80  0.39
Rifampin (D-LAK120-A) 9.33  4.38 59.8  1.39
Rifampin (D-LAK120-HP13) 8.88  1.44 14.6  2.91
Capreomycin (D-LAK120-A) 0.58  0.24 0.46  0.18
Capreomycin (D-LAK120-HP13) 0.52  0.28 0.67  0.28
D-LAK120-A (rifampin) 0.91  0.05 1.56  0.17
D-LAK120-A (capreomycin) 0.09  0.01 0.62  0.07
D-LAK120-HP13 (rifampin) 0.75  0.22 0.77  0.08
D-LAK120-HP13 (capreomycin) 0.14  0.01 0.85  0.15
TABLE 2 FICs of D-LAK peptides combined with rifampin or capreomycin against
M. smegmatis mc2 155 in the presence or absence of tyloxapol
Antimicrobial combination
Mean FIC  SE with:
Tyloxapol No tyloxapol
Rifampin  D-LAK120-A 1.58  0.10 2.50  0.14
Rifampin  D-LAK120-HP13 1.64  0.03 0.81  0.02
Capreomycin  D-LAK120-A 0.45  0.13 0.71  0.05
Capreomycin  D-LAK120-HP13 0.53  0.20 0.97  0.20
M. smegmatis HR-MAS NMR
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threshold for synergism. Under these conditions, only approximately 1/10 of the
amount of D-LAK120-A is required for the same effect. A similar effect is seen when
capreomycin is used in combination with D-LAK120-HP13, but the synergistic effect is
more modest in both the presence and absence of tyloxapol. Rifampin demonstrates
no synergy with D-LAK120-A, and these antibiotics may even be antagonistic when no
tyloxapol is added to the growth medium. In contrast, though modestly, D-LAK120-
HP13 may assist the activity of rifampin, and a little less than half as much rifampin is
required to achieve the same inhibitory effect as when rifampin is used alone. Analo-
gous experiments were performed with isoniazid, but no synergism was detected with
either peptide, and hence, these combinations were not studied further in the present
work.
DPH anisotropy and laurdan fluorescence indicate substantial changes in
membrane physical properties when M. smegmatis is cultured in the presence of
capreomycin or tyloxapol. DPH fluorescence polarization or fluorescence anisotropy
analysis is commonly used to determine changes in bacterial cytoplasmic membrane
fluidity under environmental stress (28).
As a polyene hydrophobic dye, DPH localizes to the hydrophobic core of lipid
bilayers. It aligns parallel to the acyl chains of lipids, and hence, its ability to reorient is
dependent on the packing of its lipid neighbors. A high degree of orientation and,
hence, fluorescence anisotropy results from a more rigid lipid bilayer. Significant
increases (P  0.05) in DPH fluorescence polarization anisotropy (r) were observed for
M. smegmatis mc2 155 challenged during growth with 0.75 MIC or FIC of capreomycin
or its combinations with D-LAK120-A or D-LAK120-HP13 (Fig. 3A) or when grown in the
presence of 0.025% tyloxapol, the latter producing a more modest increase. Small
increases in fluorescence anisotropy were observed when bacteria were challenged
with the D-LAK peptides or with rifampin, either alone or in combination with the
D-LAK peptides, but these were not significant compared with the results for unchal-
lenged bacteria. Only challenge with capreomycin alone or in combination with either
D-LAK peptide causes a substantial increase in membrane rigidity in M. smegmatis.
Laurdan is a solvatochromic fluorescent dye which inserts into lipid bilayers with the
fatty acid chain embedded in the hydrophobic core of the bilayer and the N,N-
dimethyl-2-napththylamine in the more polar interfacial region. The dipole moment
between the dimethylamino and carbonyl moieties is sensitive to local changes in
polarity, which will shift the emission maximum. Calculating the difference in emission
at 440 and 490 nm generates a generalized polarization (GP) value from which
membrane order can be inferred. As a lipid bilayer becomes disordered, more water can
penetrate the interfacial region, which becomes more polar, and the GP value de-
creases (29).
The GP value is therefore a measure of disorder in the lipid bilayer interfacial region,
although other factors may influence the polarity of the environment in which the
fluorophore is located and some caution is advisable when interpreting laurdan GP in
biological systems. Nevertheless, laurdan generalized polarization has been used in,
e.g., Bacillus subtilis to detect the effect of challenge with a synthetic cyclic hexapeptide,
cWFW (30), and analyzing the organization of the bacterial membrane by flotillins
(31) and MreB (32). Significant changes (P  0.05) in laurdan GP were observed for
M. smegmatis mc2 155 challenged during growth with 0.75 MIC or 0.75 FIC of capreo-
mycin or its combination with D-LAK120-A or D-LAK120-HP13 (Fig. 3B). Again, a change
in membrane properties was detected for bacteria incubated with tyloxapol, but a
noticeable reduction in GP following challenge with rifampin is nonsignificant. The
change in GP for bacteria challenged with combinations of capreomycin is of a lower
magnitude than that observed when the bacteria are challenged with capreomycin
alone, but the differences between these three conditions are nonsignificant. Notably,
the GP values under each of the conditions were reduced relative to those of the
unchallenged bacteria, which implies that the local environment of the laurdan probe
is becoming more polar, something that would normally be associated with an increase
in disorder in the interfacial region. Since the increase in DPH anisotropy for these
Man et al.
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conditions is associated with an increase in membrane rigidity, a less ordered but more
rigid membrane is perhaps surprising. The strong correlation between the DPH and
laurdan data (Fig. 3C) does, however, indicate that the two techniques are reporting on
the same event. The DPH dye would be expected to reside deep within the hydropho-
FIG 3 Fluorescence spectroscopic perspective of the response of M. smegmatis mc2 155 to challenge
with antibiotics. Data are shown for DPH fluorescence anisotropy (A), laurdan GP fluorescence (B), and
correlation (R2  0.856) of the results for DPH and laurdan (C). **, P  0.05 with respect to the results
for 7H9O (growth media alone).
M. smegmatis HR-MAS NMR
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bic core of the membrane, while the laurdan probe would be much closer to the
aqueous surface. Consequently, it is possible that the result ofM. smegmatis responding
to the presence of capreomycin is to modify the hydrophobic core of the membrane,
reducing fluidity, while the interfacial region becomes more disordered. While the
precise locations of both dyes in the mycobacterial cell membranes are yet to be
determined, it can be concluded that the physical properties of the bacterial envelope
are substantially altered in response to challenge with capreomycin but not with either
rifampin or the D-LAK peptide.
HR-MAS 1H NMR metabolomics reveals substantial changes in M. smegmatis
membrane components. Cross-validated orthogonal projections to latent structures
discriminant analysis (OPLS-DA) was used to identify significant changes in 1H HR-MAS
spectra obtained for M. smegmatis mc2 155 when challenged with 0.75 MIC of individ-
ual antimycobacterial drugs, 0.75 FIC of their combinations, or 0.025% tyloxapol. The
technique could determine significant differences, as determined by Q2 (quality assess-
ment statistic) (Table 3), for each model in which loadings were compared in a
hierarchical clustered heatmap (Fig. 4A). Volcano plots for individual comparisons allow
the identification of the magnitude and significance of changes in individual metabo-
lites (Fig. 4B to F), while changes in key metabolites are compared across treatments to
show the impact of each peptide, rifampin, capreomycin, and their combinations
(Fig. 5).
Culturing M. smegmatis mc2 155 in the presence of 0.025% tyloxapol causes
significant and substantial changes in several metabolites and components of the
mycobacterial membrane (Fig. 4B). An increase in the amount of glutamate in the cells
is the greatest change, while there are highly significant reductions in lipid resonances
associated with mycolic acid, including the saturated alkyl chains –(CH2)n- and both
R2CH-COOH and R2CH-OH. Notably, resonances associated with unsaturated alkyl
groups –CHCH- and -CH2-CHCH- are unaffected (Fig. 4B and 5A) to D). Mycobac-
terial mycolic acids comprise a long-branch mero chain of 40 to 60 carbons and a short
 branch of typically 24 carbons. The shorter  chain is completely saturated. Mero-
mycolic acids in other mycobacteria contain cyclopropanated mycolic acids, but these
are uncommon in M. smegmatis, where the major mycolic acids are a homologous =
series containing just a cis-alkene in the mero chain (33–37). An appreciation of the
composition of mycolic acids in various mycobacteria can be obtained from two recent
reviews (33, 34).
Since the fold changes in all four lipid resonances are similar, this is consistent with
a reduction in the number of saturated  chains, with mero-mycolic acids, which
contain unsaturated hydrocarbons, unaffected. Many of these differences are also
observed when M. smegmatis mc2 155 is challenged with either rifampin or capreo-
mycin (Fig. 4E and F).
However, the magnitudes of the responses vary substantially, and there are also
qualitative differences, most notably since both rifampin and capreomycin cause
TABLE 3 Test and permutated Q2 (quality assessment statistic) scores for OPLS-DA
models of 1H HR-MAS spectra of M. smegmatis mc2 155a
Treatment Q2 Q2 (permutated)
Tyloxapol (0.025%) 0.866 0.377
D-LAK120-A 0.769 0.423
D-LAK120-HP13 0.729 0.360
Rifampin 0.581 0.426
Rifampin  D-LAK120-A 0.763 0.410
Rifampin  D-LAK120-HP13 0.430 0.429
Capreomycin 0.881 0.347
Capreomycin  D-LAK120-A 0.775 0.367
Capreomycin  D-LAK120-HP13 0.823 0.344
aComparison of test and permutated Q2 scores for cross-validated OPLS-DA models comparing 1H HR-MAS
spectra of unchallenged M. smegmatis mc2 155 with those obtained for bacteria under the indicated
conditions.
Man et al.
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FIG 4 Capreomycin and rifampin induce substantial changes in mycolic acid lipid components in M. smegmatis. (A) Hierarchical
clustered heatmap comparing loadings obtained from cross-validated OPLS-DA of 1H HR-MAS NMR spectra of M. smegmatis mc2
155 grown under the indicated conditions. (B to F) Volcano plots are shown for individual comparisons of unchallenged bacteria
and those challenged with 0.025% tyloxapol (B), D-LAK120-A (C), D-LAK120-HP13 (D), rifampin (E), or capreomycin (F). Volcano plots
are of PQN normalized data and allow comparison of fold changes and significance for each metabolite. Blue, significant reductions;
red, significant increases; gray, nonsignificant changes in the indicated metabolites.
M. smegmatis HR-MAS NMR
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reductions in resonances associated with unsaturated alkyl chains. It is notable that the
fold changes in the differing lipid resonances are again similar. This is consistent with
a reduction in the number of intact mycolic acid molecules rather than a shortening in
the length of the mycolic acid alkyl chain. Since resonances for both saturated and
unsaturated hydrocarbons are reduced, as well as those for the R2CH-OH and R2CH-
COOH protons, a general reduction in mycolic acid can be inferred.
Mycolic acids are an important component of the mycomembrane. The inner leaflet
is formed of mycolic acid linked to arabinogalactan, which is in turn linked to pepti-
doglycan. The outer leaflet is also formed of lipids based on mycolic acid, but these are
FIG 5 Univariate analysis of relative metabolite levels inM. smegmatismc2 155 under the indicated conditions. Significant differences with respect to the results
for unchallenged bacteria, as determined by one-way ANOVA with Tukey’s post hoc test, are indicated (**). Other significant differences are described in the
text.
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considered free to diffuse laterally. These lipids are trehalose dimycolate (TDM) and
trehalose monomycolate (TMM). Interestingly, only challenge with capreomycin in-
duces any change in signal intensity attributable to trehalose (Fig. 4F). The significant
increase is of a magnitude similar to the decrease observed for the mycolic acid
resonances, indicating that the ratio of mycolic acid to trehalose is substantially altered
in M. smegmatis following challenge with capreomycin. This would be consistent with
a shift in the balance of TDM and TMM, to favor the latter, in the outer leaflet of the
mycomembrane.
The scale of the reduction in the mycolic acid resonances caused by capreomycin
(Fig. 4F) is much greater than that caused by rifampin (Fig. 4E) or even tyloxapol
(Fig. 4B). When changes in mycolic acid lipid resonances are compared across the
various challenges (Fig. 5A to D), it is clear that capreomycin has a substantial impact
on those from both saturated and unsaturated hydrocarbons and that, while significant
(P 0.05), the reductions in intensity due to rifampin are much more modest. Similarly,
tyloxapol causes a modest reduction in resonances from saturated hydrocarbons
(Fig. 5C and D) but has no significant effect on those from unsaturated hydrocarbons
(Fig. 5A and B). Unlike capreomycin, neither rifampin nor tyloxapol induces a significant
increase in resonances attributable to trehalose (Fig. 5F). The remodeling of mycolic
acid induced by rifampin and tyloxapol is therefore much subtler than that induced by
capreomycin, and this is presumably the origin of the nonsignificant changes in
membrane physical properties detected as described above using fluorescence tech-
niques.
The response of M. smegmatis mc2 155 to challenge with 0.75 MIC of the two D-LAK
peptides is quantitatively and qualitatively different from the response to either
rifampin or capreomycin. Although the OPLS-DA models for challenge with either
peptide indicate a significant response when all metabolites are considered (Table 3;
Fig. S3 in the supplemental material), the magnitudes of changes in individual meta-
bolites are low and few changes pass a stringent significance threshold (Fig. 4C and D).
When comparing individual metabolites across the various conditions, both peptides
trigger an increase in glutamate in the bacteria (P  0.05); a similar effect is seen for
capreomycin but not rifampin (Fig. 4E). In contrast with the results for capreomycin,
neither peptide triggered any change in trehalose (Fig. 5F). The proline-containing and
proline-free peptides can themselves be distinguished by the absence of any changes
in lipid resonances in response to D-LAK120-A, while significant (P  0.05) reductions
in lipid resonances are observed for both unsaturated and saturated hydrocarbons in
response to D-LAK120-HP13 (Fig. 5A to D).
HR-MAS 1H NMR data were also obtained for M. smegmatismc2 155 challenged with
combinations of each D-LAK peptide and either rifampin or capreomycin. For syner-
gistic combinations, the amount of each antibiotic was substantially lower than that
used for each antibiotic alone. Modest synergism exists between D-LAK120-A and
capreomycin, but there is indifference or even antagonism between D-LAK120-A and
rifampin. D-LAK120-A mitigates the reduction in saturated and unsaturated hydrocar-
bons and increase in trehalose due to capreomycin (P 0.05) (Fig. 5A to D; Fig. S1A and
S2A and B), but not the increase in glutamate (Fig. 5E). The responses of M. smegmatis
mc2 155 to rifampin and rifampin plus D-LAK120-A are indistinguishable (Fig. 5; Fig. S1C
and S2).
In combination susceptibility testing, D-LAK120-HP13 has a mostly additive effect
when used in combination with capreomycin but experiences modest synergism with
rifampin. D-LAK120-HP13 has a weaker impact on metabolic changes induced by
capreomycin or rifampin. Although the magnitudes of reduction of lipid resonances in
bacteria treated with D-LAK120-HP13-plus-capreomycin combinations were consis-
tently lower than that observed when capreomycin was used alone (Fig. 5A to D;
Fig. S1B and S2A and B), the mitigation was in no case significant. In contrast, although
the magnitudes of changes induced by rifampin were smaller, significant mitigation
(P  0.05) was observed for lipid -CH3 (Fig. 5C), while for other metabolites, the
combination of D-LAK120-HP13 and rifampin did not induce significant changes with
M. smegmatis HR-MAS NMR
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respect to the results for the unchallenged bacteria (Fig. 5A, B, and D). Notably, the
volcano plot of the individual comparisons indicates that no metabolites were signif-
icantly changed when this combination was used (Fig. S1D), in contrast to the results
for rifampin (Fig. 4F) or, indeed, D-LAK120-HP13 when used alone (Fig. 4D).
Increased membrane rigidity is associated with altered composition of the
mycomembrane. To better understand the contributions of the various changes in
metabolite concentrations to the physical properties of the mycomembrane following
challenge with capreomycin and/or D-LAK peptides or growth in the presence of
0.025% tyloxapol, Spearman correlations between individual metabolites and the
fluorescence anisotropy data recorded for the same samples were determined using
partial least-squares regression (Fig. 6; Fig. S6). Significant (P  0.0001) correlations
were detected between fluorescence anisotropy data and each of the metabolites in
which substantial changes resulted from challenge with capreomycin, D-LAK120-HP13,
or growth in the presence of 0.025% tyloxapol. The strongest of these correlations were
negative correlations with saturated hydrocarbons (Fig. 6A and E), while weaker
negative or positive correlations were detected with, respectively, unsaturated hydro-
carbons (Fig. 6C and D) or trehalose (Fig. 6B). The strength of these correlations may
reflect the impact of each component of the mycomembrane in determining its fluidity,
or this may reflect the observation that, while all three types of resonance are affected
by challenge with capreomycin, D-LAK120-HP13 affects only lipid resonances and
FIG 6 Increased membrane rigidity is associated with altered composition of the mycomembrane. Spearman correlations are shown between DPH anisotropy
(r) and 1H HR-MAS NMR resonance intensity data obtained forM. smegmatismc2 155 grown without challenge or with 0.025% tyloxapol or 0.75 MIC D-LAK120-A,
D-LAK120-HP13, capreomycin, capreomycin plus D-LAK120-A, or capreomycin plus D-LAK120-HP13. Data are shown for lipid –(CH2)n- (A), trehalose (B), lipid
–CHCH- (C), lipid –CH2-CHCH- (D), and lipid -CH3 (E).
Man et al.
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tyloxapol affects only saturated hydrocarbons in the shorter  chain. Nevertheless, the
increased rigidity of the mycomembrane appears to be a direct result of the observed
changes in its composition.
Rifampin but not capreomycin induces detectable changes in metabolite com-
position of spent medium. Spent bacterial culture supernatants were also analyzed by
OPLDS-DA (Fig. S7). Comparison of the models indicates that only under those condi-
tions where rifampin was present was any qualitative change in M. smegmatis metab-
olism detected (Fig. S7A). A binary comparison of spent medium from M. smegmatis
grown without challenge to fresh medium reveals that the bacteria consume glucose
and produce tartrate and 2-hydroxyisobutyrate (Fig. S7B). When challenged with
rifampin, there were slight increases in glucose and citrate consumption but substan-
tially reduced production of lactate, alanine, valine, and pyruvate and more modest
reductions in the production of malate and tartrate (Fig. S7C). These changes were
muted when rifampin was applied in combination with D-LAK120-HP13, where in-
creased consumption of glutamate was also observed (Fig. S7D). Under no other
conditions were any changes in individual metabolites detected that passed the
significance threshold.
DISCUSSION
The combination of HR-MAS 1H NMR metabolomics and fluorescent probes sensitive
to changes in membrane fluidity and order reveals modest changes in the mycomem-
brane of M. smegmatis mc2 155 in response to challenge with rifampin but much more
dramatic changes in response to challenge with capreomycin. The D-LAK peptides
cannot be distinguished based on any change in the physical properties of the
mycomembrane, but changes in its composition reflect distinct mechanisms for the
proline-free and proline-containing analogues. The combinations of both D-LAK pep-
tides with capreomycin are synergistic in the presence of tyloxapol, but when M. smeg-
matis is cultured in the absence of tyloxapol, this is attenuated, leaving only modest
synergy and only with D-LAK120-A and not D-LAK120-HP13; only the latter is modestly
beneficial when combined with rifampin. These findings may provide a rationale for
understanding the properties required for D-LAK peptides and related molecules to
potentiate the activities of first- and second-line treatments against mycobacterial
infections and understand whether there is more to the activity of either peptide than
enhancing penetration of the mycomembrane.
Capreomycin acts by inhibiting protein synthesis but induces substantial re-
modeling of the mycomembrane. The antibiotic activity of capreomycin against both
M. smegmatis and M. tuberculosis is ascribed to its ability to inhibit protein translation
by interfering with the function of ribosomes (38). Specifically, capreomycin binds
across the ribosomal subunit interface using tlyA-encoded methylations in both 16S
and 23S rRNAs (39). A transcriptomic approach to understanding the mechanism of
action of capreomycin in M. tuberculosis confirmed the importance of this mechanism
but additionally revealed substantial changes in a variety of other gene classes,
including genes involved in lipid metabolism, cell wall and cell processes, and inter-
mediary metabolism and respiration (40). Notably, capreomycin was shown to affect
the glyoxylate shunt, an alternate pathway to the TCA cycle, with upregulation of icl
(Rv0467, encoding isocitrate lyase), glcB (Rv1837c), and aceAa (Rv1915), presumably
stimulating a process where fatty acids become an important carbon source. There was
reduced expression of a block of genes associated with the electron transport chain,
coding for NADH dehydrogenase or NADH-ubiquinone oxidoreductase, as well as gdh,
a probable NAD-dependent glutamate dehydrogenase. Though performed in M. smeg-
matis, the present study is consistent with these findings; glutamate is seen to accu-
mulate following challenge with capreomycin (and also both D-LAK peptides), while
the substantial reduction in mycolic acid is consistent with fatty acids being diverted for
use as a carbon source; notably, in contrast with the results for rifampin challenge, no
significant changes in individual metabolite levels in spent culture medium were
detected. There are some important differences in both the composition of the
M. smegmatis HR-MAS NMR
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mycomembrane (33, 34) and the metabolism of these two and other Mycobacterium
species. Nevertheless, taken together, the two studies indicate that there is likely a
substantial shift in metabolism following capreomycin challenge in both M. smegmatis
andM. tuberculosis, resulting in greater consumption of fatty acids, depletion of mycolic
acid, and rigidification of the mycomembrane. As such, this response from mycobac-
teria to capreomycin challenge affords a means of altering the barrier that other
antimicrobials may have to cross to reach their targets.
Rifampin acts by inhibiting transcription and induces modest remodeling of
the mycomembrane. The antibiotic activity of rifampin is attributed to its ability to
inhibit bacterial-DNA-dependent RNA polymerase activity. M. tuberculosis is more
susceptible to rifampin than M. smegmatis, with the latter enjoying a higher level of
baseline resistance due to rifampin ADP ribosyltransferase, an enzyme capable of
inactivating rifampin (41). However, exposure of rifampin-sensitive M. tuberculosis
H37Rv to rifampin induces changes in the expression of genes in the same functional
classes affected by capreomycin challenge, i.e., lipid metabolism, cell wall and cell
processes, and intermediary metabolism and respiration (42). Furthermore, rifampin, as
well as isoniazid and streptomycin, triggers the activation of isocitrate lyases in M. tu-
berculosis (43), suggesting that the glyoxylate shunt is a general means of overcoming
oxidative stress (44). Antimicrobial peptides, including LL-37 and pleurocidin, have
been shown to induce oxidative stress in Escherichia coli and Candida albicans, respec-
tively, (45, 46). The modest changes in mycolic acids induced by challenge with
rifampin or D-LAK120-HP13 may therefore be indicative of oxidative stress and reflect
penetration of the bacterium; notably, D-LAK120-A does not have this effect. The
response of M. smegmatis to rifampin differs from that to capreomycin not only
quantitatively in the HR-MAS study but qualitatively in the study of spent culture
composition, where evidence for an alternate strategy for overcoming oxidative stress
emerges. This would be consistent with M. smegmatis altering its metabolism in
response to rifampin in a way similar to that used in response to capreomycin but less
reliant on the metabolism of fatty acids.
Distinct membrane activities underpin synergistic combinations. For antibiotics
to have additive or synergistic effects when used in combination, they need to avoid
both interactions that reduce the amount of each agent reaching their target(s) and the
triggering of responses in the bacteria that counter the activity of the other agent. For
combinations of antibiotics to have synergistic effects, they additionally need to act on
different targets or have distinct effects on the same target, such that the effect of each
individual antibiotic is enhanced. The HR-MAS 1H NMR approach enables the investi-
gation of whether antibiotics do indeed differ in their effects on the mycomembrane.
This is achieved by obtaining a bacterial perspective of the challenge and inferring
differences in the activity of each antibiotic from differences in the response of the
bacteria to each challenge. Capreomycin, rifampin, the D-LAK peptides, and tyloxapol
each induce qualitatively and/or quantitatively different responses from M. smegmatis,
but there is nevertheless considerable overlap.
Tyloxapol improves the potency of rifampin and D-LAK peptides when used alone,
but the combination of D-LAK peptides and rifampin is indifferent in the presence of
tyloxapol. Since both rifampin and tyloxapol induce membrane remodeling in M. smeg-
matis, one might speculate that rifampin and tyloxapol combine to produce substantial
change in the mycomembrane that inhibits the ability of D-LAK peptides to disrupt or
penetrate the membrane. In the absence of tyloxapol-dependent improvements in
rifampin potency, the change in membrane properties induced by rifampin alone may
differentially affect the two AMPs. This may therefore explain why combinations of
rifampin with D-LAK120-A fare worse, indeed being antagonistic, than those containing
D-LAK120-HP13. One hypothesis could be that the proline modification of the latter
enables this analogue to better penetrate the mycomembrane.
Both D-LAK peptides interact synergistically with capreomycin, albeit modestly. The
interaction is enhanced, however, when M. smegmatis is cultured in the presence of
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0.025% tyloxapol. While tyloxapol enhances the action of both peptides and rifampin,
this is not the case for capreomycin (within the margin of error). It is unlikely, therefore,
that tyloxapol improves access for capreomycin, though it may perform this function
for either D-LAK peptide. Although the difference between the two peptides in terms
of their interaction with capreomycin is small, D-LAK120-A consistently outperforms
D-LAK120-HP13. Both peptides seemingly have a similar effect on capreomycin activity,
but the poorer synergy between D-LAK120-HP13 and capreomycin may be related to
the ability of both agents to trigger changes in the mycomembrane. Since both
capreomycin and rifampin trigger changes in the mycomembrane composition, albeit
with very different magnitudes of response, this argument seemingly runs counter to
the idea that membrane interactions will determine the ability of such molecules to
interact synergistically against M. smegmatis. The answer to this may lie in the distinct
physical properties of capreomycin and rifampin. Capreomycin is a cationic molecule
with a physiological net positive charge of four. Rifampin is also cationic, but its
physiological charge is only one. Both molecules must penetrate the bacteria to exert
their main antibiotic effects, and hence, the D-LAK peptides, with a net positive charge
of nine and a higher affinity for anionic components of the mycomembrane, may
provide an important screen for interactions between the membrane and either
capreomycin or rifampin. Capreomycin, with the higher charge, would benefit more
from this screen, and this may underlie the observed synergy, rather than any induced
change in the biophysical properties of the mycomembrane.
Conclusion. The combination of HR-MAS 1H NMR and fluorescence spectroscopy
reveals how the remodeling of the mycomembrane in response to antibiotics, most
notably capreomycin, may affect their ability to penetrate or act in combination with
other antibiotics against mycobacteria. Furthermore, the approach can distinguish the
activities of two D-LAK peptide analogues, based on the different responses ofM. smeg-
matis to AMP challenge and combinations of AMPs and rifampin or capreomycin.
Understanding how mycobacteria respond to antibiotics, in particular by remodeling
the mycomembrane through which many antibiotics must pass to be effective, may be
essential in designing effective antibiotic combinations.
MATERIALS AND METHODS
Mycobacterium smegmatis mc2 155 was grown in Middlebrook 7H9 broth (catalog number 271310;
Difco, Detroit, MI) enriched with 10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC) (catalog
number 212240; Becton, Dickinson, Franklin Lakes, NJ) and 0.5% (vol/vol) glycerol (catalog number
G-5516; Sigma-Aldrich) in 50-ml Falcon tubes at 37°C without shaking. A concentration of 0.025%
(vol/vol) tyloxapol surfactant (catalog number T8761; Sigma-Aldrich) was added as one of the treatments.
Rifampin (RIF; catalog number R3501) and capreomycin sulfate (CAP) from Streptomyces capreolus
(catalog number C4142) were from Sigma-Aldrich. D-AMPs D-LAK120-A (KKLALALAKKWLALAKKLALALA
KK-NH2) and D-LAK120-HP13 (KKALAHALKKWLPALKKLAHALAKK-NH2) were supplied by China Peptides
Co., Ltd. (Shanghai, China). The purity of synthesized peptides was above 80%, and the peptides were
used as supplied. Both peptides were amidated at the C terminus.
MIC and FIC. The MICs of the anti-TB agents (rifampin, D-AMPs, and capreomycin) against M. smeg-
matis mc2 155 were determined using the broth microdilution assay in 96-well plates. Twofold serial
dilutions in duplicate were made in Middlebrook 7H9 broth supplemented with OADC and glycerol. An
inoculum at an optical density at 600 nm (OD600) of 0.02 was prepared by diluting mid-log cultures, and
100 l was added in each well (~1 105 CFU). Amounts of 100 l each of mycobacterial suspension and
anti-TB agent were added in each well to obtain the inoculum concentration of 5  104 CFU/ml. Growth
controls using no drug and sterile medium were prepared in each assay. The plates were then incubated
at 37°C for 24 h before adding 30 l of 0.02% (wt/vol) resazurin dye, and the color change was evaluated
after incubation for another 24 h.
The fractional inhibitory concentrations (FICs) of the combination treatments of rifampin or capreo-
mycin and D-AMPs were determined using a checkerboard assay (47). Synergistic interactions between
anti-TB agents in combination treatments were denoted by the fractional inhibitory concentration (FIC)
index. The FIC values of the combinations were calculated from the following formula: FIC index 
FICA  FICB  [A]in combination/MICA  [B]in combination/MICB.
Confocal microscopy. M. smegmatis mc2 155 (1.1  108 CFU/ml) at mid-log phase (OD  0.6) was
treated with 250 g/ml FITC-labeled, 150-kDa dextran (catalog number 46946; Sigma-Aldrich) and a
D-AMP (D-LAK120-A or D-LAK120-HP13) or rifampin at the respective MIC for 20 min. Following
treatment, the bacterial cells were centrifuged at 7,500 rpm for 10 min and washed three times with
phosphate-buffered saline (PBS). Cells were then fixed in 2% formaldehyde at room temperature (RT) for
20 min. After fixation, the cells were washed twice and resuspended in PBS. Amounts of 20 l of sample
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were then allowed to air dry on microscope slides overnight. Samples were then imaged with a 65 oil
immersion objective lens using a Zeiss LSM-510 inverted confocal microscope (Carl Zeiss, Inc.). FITC was
excited with a 488-nm laser and detected with a 505-nm long-pass filter.
TEM. M. smegmatis mc2 155 (1  107 CFU/ml) at mid-log phase (OD  0.6) was treated with
D-LAK120-A and D-LAK120-HP13 at their respective MICs for 5 and 30 min. Samples were washed three
times with PBS, and cell pellets were collected by centrifugation. Cell pellets were then fixed in 2.5%
glutaraldehyde until further processing. Samples were rinsed thrice with PIPES [piperazine-N,N=-
bis(ethanesulfonic acid)] buffer (catalog number P6757; Sigma-Aldrich), followed by a second fixation in
1% osmium tetroxide (OsO4) (catalog number 75632; Sigma-Aldrich) for 1 h at RT, first embedding into
agar to reduce sample loss. Pellets were then dehydrated using ethanol (EtOH) (50, 70, and 90% for
10 min each and 3 times at 100% for 20 min). After dehydration, samples were infiltrated with a 1:1 epoxy
resin-propylene oxide mixture overnight at 37°C. The next day, pellets were infiltrated with fresh epoxy
resin for 1 h at 37°C, followed by polymerization at 60°C overnight in plastic molds. Samples were viewed
using a Philips CM100 transmission electron microscope equipped with a TENGRA 2.3-megapixel by
2.3-megapixel camera.
Anti-TB agent challenge assays. To evaluate the mechanisms of action of anti-TB agents on
bacterial growth, a 0.75 MIC challenge assay was conducted to observe the growth response of
M. smegmatis mc2 155. A 1% inoculum in the presence of 0.75 MIC of each anti-TB agent, alone or in
combination, was cultured in 10 ml Middlebrook broth medium at 37°C. After 5 days, the bacteria were
processed and subjected to trans-1,6-diphenyl-1,3,5-hexatriene (DPH) fluorescence assay and laurdan
fluorescence emission and nuclear magnetic resonance (NMR) metabolomics analyses.
DPH fluorescence assay. An M. smegmatis mc2 155 bacterial suspension was harvested and fixed
using 0.25% formaldehyde for 1 h at room temperature. After fixing, the bacterial cells were centrifuged
at 5,000 rpm and 4°C for 8 min and then washed with 5 ml PBS once. Bacteria were resuspended in PBS
and stained with 2.5 M DPH fluorescence probe. All tubes were wrapped with foil to prevent light
degradation of the dye and incubated at 37°C for 30 min. Single-wavelength measurements were taken
at 430-nm emission and 358-nm excitation using a Varian Cary Eclipse fluorescence spectrophotometer
(Agilent, Santa Clara, CA). The spectral bandwidth of the emission monochromator and the measurement
of emission spectra were set at 10 nm. Steady-state fluorescence anisotropy, r, was calculated with the
formula r  (IVV  GIVH)/[IVV  2(GIVH)], where IVV and IVH are the parallel and perpendicular polarized
fluorescence intensities measured with the vertically polarized excitation light, IHV and IHH are the same
fluorescence intensities measured with the excitation light horizontally polarized, and G is the mono-
chromator grating correction factor given by G  IHV/IHH.
Laurdan fluorescence assay. M. smegmatis mc2 155 bacterial pellets were harvested, fixed, and
washed as described above and then stained with 2.5 M laurdan (6-dodecanolyl-N,N-dimethyl-2-
napthtylamine) fluorescence probe. All tubes were wrapped with foil to prevent light degradation of the
dye and incubated at 37°C for 1 h. Twenty emission wavelength spectra, from 400 to 600 nm, were
obtained with excitation at 350 nm on the same fluorescence spectrophotometer. The general polar-
ization (GP) value corresponding to the fluidity of the membrane was calculated using the formula GP 
(I440 I490)/(I440 I490), where I440 and I490 are the emission intensities at the corresponding wavelengths.
NMR metabolomics. An M. smegmatis mc2 155 bacterial suspension was pelleted by centrifugation
at 5,000 rpm, 4°C, for 8 min. Supernatant was collected and filtered through 0.22-m membrane filters
to remove any remaining bacterial cells. The bacterial pellet was washed twice and resuspended in PBS.
All supernatant samples were frozen at 80°C, and pellets were snap-frozen in liquid nitrogen before
freeze drying using an Alpha 1-2 LDplus freeze dryer (Martin Christ, Germany). After lyophilization, the
supernatant was rehydrated by using 10% D2O containing 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid
sodium salt (TSP-d4) to provide a deuterium lock signal with a reference signal. Samples were then
transferred to NMR tubes. 1H NMR spectra were recorded on a Bruker Avance II 700 NMR spectrometer
(Bruker BioSpin, Coventry, United Kingdom) equipped with a 5-mm helium-cooled quadruple resonance
cryoprobe, with nine sample replicates tested per condition and all kept at 4°C. One-dimensional (1-D)
spectra were recorded under automation at 298 K using a Carr-Purcell-Meiboom-Gill presaturation
(cpmgpr1) pulse sequence. Spectra were acquired with 64 transients, a spectrum width of 20.1 ppm, and
65,536 data points. For the freeze-dried bacterial pellets, 40 l of D2O was used for rehydration. The
resuspended samples were placed in Kel-F inserts and then in the 4-mm zirconia magic angle spinning
(MAS) rotor and preserved with a Kel-F cap (Bruker, Rheinstetten, Germany). Data acquisition was
performed on a 600 MHz Bruker Avance III spectrometer equipped with a 4-mm HR-MAS probe, keeping
the temperature at 310 K. The spinning speed was 5 kHz. 1H NMR spectra were collected with a
pulse-acquire with presaturation (zgpr) pulse sequence, a spectrum width of 12.01 ppm, and a relaxation
delay (d1) of 3 s. The total acquisition time was 1.14 s, with a prescan delay of 6.5 s. A total of 128 scans
were used to obtain each of the NMR spectra. The free induction decay was multiplied by an exponential
function with line broadening of 0.3 Hz. To aid the assignment of metabolite resonance, correlation
spectroscopy (COSY) (cosygpprqf) spectra were acquired for a subset of samples. All peak positions were
measured relative to the methyl peak of TSP-d4, set to 0.0 ppm. Phase correction of spectra was
performed manually, and automatic baseline correction was applied.
Data analysis and statistics. All microbial data presented in this study were statistically analyzed by
using GraphPad Prism (version 5.01 for Windows; GraphPad Software, Inc., La Jolla CA). One-way analysis
of variance (ANOVA) was performed, followed by Dunnett’s multiple-comparison test with a value of P
0.05 to establish statistical significance. Sigmoidal dose-response (variable slope) was used for fitting of
growth inhibition calculations. All experiments were performed at least 3 times.
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For metabolomics data, peak assignment was performed by comparing chemical shift values and
multiplicities from J-resolved NMR spectra to values from the Biological Magnetic Resonance Bank
(BMRB) (48), COSY spectra, and NMR metabolite templates in Chenomix NMR suite software (Chenomx,
Inc., Edmonton, Canada). Multivariate data analysis was based on previously published work (49).
Principal-component analysis (PCA) and orthogonal projections to latent structures discriminant analysis
(OPLS-DA) were done using MVAPACK (50) and software developed in our previous study (49). Spectra
were subjected to probabilistic quotient normalization (PQN) and autoscaled (51). The icoshift algorithm
was applied for further alignment, and an optimized bucketing algorithm with a 0.005-ppm bin size was
employed for bucketing. Cross-validation was performed as described previously (49), with the modifi-
cations that 85% of the samples were used as a training set and the remaining 15% as a test set and a
maximum of 5 components were used. Double cross-validation was repeated 1,000 times, producing 7
1,000 models. The reference Q2 value was generated after the known or random class assignment
process, providing a measure of goodness of fit after cross-validation, generally considered to be good
above 0.5 (52, 53). The Q2 value quoted herein (Table 3) is the mean value of all models and was
compared between the genuine and permutated class assignments in each case. Heatmaps with
Euclidian distance-hierarchical cluster (HCL) analysis were generated by using MultiExperiment Viewer
(MeV) software.
Volcano plots and univariate analysis of metabolomics data. For volcano plots, significant results
from PLS or OPLS-DA analysis justified univariate analysis of peaks associated with predictive value in the
multivariate models. Therefore, the integrals of assigned NMR peaks were analyzed using nonparametric
univariate methods. Volcano plots were used to compare the fold changes in metabolite values between
two conditions. Fold change was calculated as the ratio between the results for the treatment condition
and the control (treatment/control). The Mann-Whitney U test was used to compare mean values, and
the associated P values were false discovery rate adjusted using the Benjamini-Hochberg method ( 
0.05). Volcano plots were generated using custom scripts in Python with the Numpy, Pandas, Matplotlib,
and Seaborn packages.
PLS regression. PLS regression was performed in Python using the PLSRegression function in the
scikit-learn software package. The initial model assessment determined that only one component was
necessary for best model performance. An increased number of components led to a decrease in Q2.
Monte Carlo cross-validation of models was performed by randomly splitting data into 70/30 training/
test set splits. Model generation and assessment were repeated 1,000 times to avoid bias by sample
separation, and R2 and Q2 values were calculated to assess model performance. The R2 metric demon-
strates how well the model describes the training data set, while Q2 is a metric of how well the model
predicts the test set.
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